Cutaneous and Mucocutaneous Leishmaniasis

• Published in: Actas dermo-sifiliográficas (English ed.) 2021-07
• Main Authors: Abadías-Granado, I, Diago, A, Cerro, P A, Palma-Ruiz, A M, Gilaberte, Y
• Format: Article
• Language: eng ; spa
• ISSN: 1578-2190
• DOI: 10.1016/j.ad.2021.02.008

Leishmaniasis is a chronic disease caused by flagellate protozoa of the genus Leishmania. It is a global disease, but most cases are seen in South America, the Mediterranean, and some areas of Asia and Africa. The 3 main types of leishmaniasis are cutaneous (the most common), mucocutaneous, and visceral (the most severe). Visceral leishmaniasis is also known as kala-azar. Leishmaniasis is diagnosed by demonstrating the presence of Leishmania amastigotes in clinical specimens using direct microscopic examination or molecular analysis. Various treatments exist, although the evidence supporting the options available for cutaneous leishmaniasis is weak. Both the classical presentation of leishmaniasis and our management of the disease have changed in recent decades because of acquired immune deficiency caused by conditions such as human immunodeficiency infection or the use of tumor necrosis factor inhibitors.